GGrantIndex
← Search

Genomics Shared Resource

$1P30FY2023CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

ABSTRACT Overview: Genetics and genomics technologies are essential tools for cancer research and help to improve care for cancer patients. The Genomics Shared Resource (GSR) provides University of Colorado Cancer Center (UCCC) members high-quality and cost-effective services and technical support for high-throughput genomic investigation to study cancer pathogenesis, therapeutics, genetic susceptibility, and biomarker development, and develop strategies for targeted and personalized medicine. Services and Expertise: GSR offers methodologies for quantitative assessment of DNA/RNA including evaluation of human and murine cells harboring shRNA and CRISPR libraries that UCCC members obtain from the Functional Genomics Shared Resource (FGSR). GSR provides genome-wide analyses of DNA sequence, transcriptomes, epigenetics and cytogenomics using next generation sequencing (NGS) and gene microarrays; and single cell genomic and transcriptomic analyses including single cell immune profiling and spatial gene expression. Equipment: GSR houses equipment to support DNA next-generation sequencing (NGS) (Illumina NovaSeq 6000 and Illumina MiSeq); single-cell genomics (10X Genomics Chromium; Mission Bio Tapestri; Fluidigm C1 and Biomark HD Systems); DNA microarray analysis (Affymetrix GeneChip systems; Illumina iScan system; and Agilent SureScan Microarray system) and Affymetrix, Agilent and Illumina microarray and sequencing software. Management: GSR is an institutional core managed by the UCCC, and is overseen by H Ford, Associate Director for Basic Research. Use of Services: Since July 2016, GSR has provided services to 432 investigators. Twenty-nine percent of users (125) were UCCC members, representing all four programs and resulting in 118 peer reviewed publications, 18% with an IF ≥ 10. Operating Budget: CCSG funding represents 2% of the annual operating budget of $4.4M. The remaining support is from user fees (98% $4.3M). Innovation and Developments: The GSR team supports UCCC members with commercial genomic tools including single cell genomics for cancer research. GSR develops and optimizes customized methods for specific cancer research applications. Consultation and Education: GSR provides consultation for designing and analyzing reliable genomics experiments in conjunction with the Biostatistics and Bioinformatics SR (BBSR) and helps members stay updated with the advancement of technology through seminars and hands-on training. Future Directions: GSR has four main future directions that are in high demand by UCCC investigators: 1) optimize 10X Genomics Visium spatial gene expression solution and methods for single cell genomics; 2) adopt Olink proteomics with NGS readouts; 3) adopt Nanopore single molecule sequencing; and 4) enhance NGS capability by continuously upgrading our technologies.

View original record on NIH RePORTER →